442 related articles for article (PubMed ID: 10163332)
1. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
Agha AH; Roy JB; Culkin DJ; Lyon K
Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
[TBL] [Abstract][Full Text] [Related]
2. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
3. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
5. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
[TBL] [Abstract][Full Text] [Related]
6. Current treatment of BPH.
Roylance P; Gibelin B; Espié J
Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
[TBL] [Abstract][Full Text] [Related]
7. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
[TBL] [Abstract][Full Text] [Related]
8. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
9. Finasteride in benign prostatic hyperplasia.
Verhamme KM; Bosch RJ; Sturkenboom MC
N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15049034
[No Abstract] [Full Text] [Related]
10. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
[TBL] [Abstract][Full Text] [Related]
11. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
12. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
Boyle P; Roehrborn C; Harkaway R; Logie J; de la Rosette J; Emberton M
Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
[TBL] [Abstract][Full Text] [Related]
13. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605
[No Abstract] [Full Text] [Related]
14. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
Hausmann R; Thalmann G; Reich O; Steif CG
Aktuelle Urol; 2004 Sep; 35(5):339-42. PubMed ID: 15383991
[No Abstract] [Full Text] [Related]
15. [Benign hypertrophy of the prostate: which treatment, for whom?].
Schulman C
Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
[TBL] [Abstract][Full Text] [Related]
16. Benign prostatic hyperplasia (BPH).
Harv Mens Health Watch; 2006 Aug; 11(1):3. PubMed ID: 17111474
[No Abstract] [Full Text] [Related]
17. Treatment and pharmacologic management of BPH in the context of common comorbidities.
O'Leary MP
Am J Manag Care; 2006 Apr; 12(5 Suppl):S129-40. PubMed ID: 16613527
[TBL] [Abstract][Full Text] [Related]
18. [Benign prostatic hyperplasia: medical therapy].
Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
[TBL] [Abstract][Full Text] [Related]
19. [Current drug therapy of benign prostatic hyperplasia].
Schmidbauer CP; Madersbacher S
Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
[TBL] [Abstract][Full Text] [Related]
20. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
Kaplan SA; Olsson CA; Te AE
J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
